Reported Phase 2 Observations

Peer-reviewed Phase 2 clinical research evaluated Retatrutide across multiple dose levels in adult study populations
with obesity-related metabolic characteristics. Over a 48-week observation period, investigators reported
dose-associated changes in body weight compared to placebo controls.
Reported mean percentage changes in body weight ranged from approximately −8.7% at lower dose levels
to −24.2% at the highest dose studied, while placebo groups demonstrated minimal change.
These findings represent aggregated study observations and do not establish clinical applicability.
(PubMed)

Liver Fat Measurements in MASLD Research

In a subset of study participants characterized with metabolic dysfunction–associated steatotic liver disease (MASLD),
researchers reported dose-dependent changes in liver fat content measured by imaging techniques.
At 24 weeks, reported reductions ranged broadly depending on dose, with continued changes observed at 48 weeks.
A proportion of participants demonstrated liver fat values below predefined thresholds used within the study design.
These outcomes reflect controlled research measurements rather than established therapeutic conclusions.
(Nature Medicine)

Research Notes

• All reported outcomes originate from controlled Phase 2 clinical research studies.
• Observed effects varied by dose, duration, and participant characteristics.
• Gastrointestinal events were among the most commonly reported study observations.
• Phase 3 studies are required to further evaluate reproducibility and broader applicability.

Sources